Miranda C. Van Der Lee

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Thyrotropin Receptor Antagonism by a Novel Small Molecule: Preclinical In Vitro Observations.

Thyrotropin Receptor Antagonism by a Novel Small Molecule: Preclinical In Vitro Observations.

Journal: Thyroid : official journal of the American Thyroid Association

Published: April 05, 2023

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.

Journal: Journal for immunotherapy of cancer

Published: March 26, 2023

Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist.

Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist.

Journal: Bioorganic & medicinal chemistry

Published: February 01, 2023

Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate.

Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate.

Journal: Molecular cancer therapeutics

Published: September 09, 2022

A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines.

A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines.

Journal: Bioconjugate chemistry

Published: July 23, 2020

Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice.

Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice.

Journal: Molecular cancer therapeutics

Published: March 30, 2018

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.

Journal: Molecular cancer therapeutics

Published: March 19, 2016

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.

Journal: Molecular pharmaceutics

Published: January 31, 2015

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.

Journal: Molecular cancer therapeutics

Published: October 09, 2014

Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.

Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.

Journal: Molecular cancer therapeutics

Published: September 06, 2014

Chemokine cooperativity is caused by competitive glycosaminoglycan binding.

Chemokine cooperativity is caused by competitive glycosaminoglycan binding.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: March 19, 2014

β-Arrestin recruitment and G protein signaling by the atypical human chemokine decoy receptor CCX-CKR.

β-Arrestin recruitment and G protein signaling by the atypical human chemokine decoy receptor CCX-CKR.

Journal: The Journal of biological chemistry

Published: January 24, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026